Cited by 43Diabetic Foot Ulcer Assessment and ManagementNitric Oxide and Endothelin EffectsWound Healing and Treatments

Single-Dose Pharmacokinetics of Different Oral Sodium Nitrite Formulations in Diabetes Patients

Open access
Greenway, Frank L., Predmore, Benjamin L., Flanagan, Douglas R., Giordano, Tony, Qiu, Yang, Brandon, Angela, Lefer, David J., Patel, Rakesh P. +1 more·2012·Diabetes Technology & Therapeutics

Abstract

Background: Diabetic foot ulcers, although associated with macrovascular disease and neuropathy, have a microvascular disease causing ischemia not amenable to surgical intervention. Nitrite selectively releases nitric oxide in ischemic tissues, and diabetes subjects have low nitrite levels that do not increase with exercise. This study explores the safety and pharmacokinetics of a single dose of sodium nitrite in subjects with diabetic foot ulcers. Subjects and Methods: Using a blinded, randomized crossover study design, 12 subjects with diabetes mellitus and active or healed foot ulcers received a single dose of sodium nitrite on two occasions 7–28 days apart, once with an immediate release (IR) formulation and once with an enteric-coated (EC) formulation for delayed release. Serum nitrite, nitrate, methemoglobin, sulfhemoglobin, blood pressure, pulse rate, complete blood count, chemistry panel, electrocardiogram, and adverse events were followed for up to 6 h after each dose. The IR and EC nitrite levels were analyzed by one-way analysis of variance and by pharmacokinetic modeling. Results: The IR formulation elevated nitrite levels between 0.25 and 0.75 h ( P <0.05). The EC formulation did not elevate nitrite levels significantly, but both formulations gave plasma nitrite levels previously suggested to be therapeutic (approximately 2–5 μM ). The IR formulation gave an asymptomatic blood pressure drop of 10/6 mm Hg ( P <0.003), and two subjects experienced mild flushing. There was no elevation of methemoglobin or other safety concerns. Pharmacokinetic modeling of plama nitrite levels gave r 2 values of 0.81 and 0.97 for the fits for IR and EC formulations, respectively. Conclusions: Oral sodium nitrite administration is well tolerated in diabetes patients.

Integrity signals

Registry

Crossref · 10.1089/dia.2011.0291

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Treatment with sodium nitrite may have beneficial cardiovascular effects in humans by acutely decreasing blood pressure.

    “there is some evidence that treatment with sodium nitrite may have beneficial cardiovascular effects in humans by acutely (by either mildly or moderately) decreasing blood pressure (32, 37, 63) (Table 1)”

    From Inorganic nitrite supplementation for healthy arterial aging (2014) · cites this paper as [63]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Greenway, F. L., Predmore, B. L., Flanagan, D. R., Giordano, T., Qiu, Y., Brandon, A., Lefer, D. J., Patel, R. P., & Kevil, C. G.
Affiliations
  • Pennington Biomedical Research Center (US)
  • Emory University (US)
  • University of Iowa (US)
  • Theravasc, Inc.
  • University of Alabama at Birmingham (US)
  • Louisiana State University Health Sciences Center Shreveport (US)
Corresponding author
Greenway, Frank L.
Venue
Diabetes Technology & Therapeutics
Published
2012-07
Volume
14
Issue
7
Pages
552-560
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W2008003710
Cited by
43
References
26
Citations by year
2026: 1 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 3 · 2015: 8 · 2014: 2 · 2013: 2
FWCI
3.08
Type
journal article
Language
en
Open access
Locations
  • Diabetes Technology & Therapeutics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (R01HL093579, R01HL092141)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Rehabilitation › Wound Healing and Treatments
Keywords
sodium nitrite, diabetic foot ulcer, pharmacokinetics, immediate-release formulation, enteric-coated formulation, nitric oxide, serum nitrite, methemoglobin, blood pressure, drug safety, diabetes mellitus
MeSH terms
Administration, Oral, Blood Pressure, Chemistry, Pharmaceutical, Chromatography, High Pressure Liquid, Delayed-Action Preparations, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Intestinal Absorption, Male, Middle Aged, Sodium Nitrite, Treatment Outcome, Diabetic Foot, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review